BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35727156)

  • 1. Use of Preoperative FDG PET/CT and Survival of Patients with Resectable Non-Small Cell Lung Cancer.
    Chen WM; Chen M; Hsu JG; Lee TS; Shia BC; Wu SY
    Radiology; 2022 Oct; 305(1):219-227. PubMed ID: 35727156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of preoperative [
    Lin JT; Li XM; Zhong WZ; Hou QY; Liu CL; Yu XY; Ye KY; Cheng YL; Du JY; Sun YQ; Zhang FG; Yan HH; Liao RQ; Dong S; Jiang BY; Liu SY; Wu YL; Yang XN
    Ann Nucl Med; 2024 Mar; 38(3):188-198. PubMed ID: 38145431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consistency and prognostic value of preoperative staging and postoperative pathological staging using
    Kajiyama A; Ito K; Watanabe H; Mizumura S; Watanabe SI; Yatabe Y; Gomi T; Kusumoto M
    Ann Nucl Med; 2022 Dec; 36(12):1059-1072. PubMed ID: 36264439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).
    Agarwal M; Brahmanday G; Bajaj SK; Ravikrishnan KP; Wong CY
    Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):691-8. PubMed ID: 19915840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.
    Finkle JH; Jo SY; Ferguson MK; Liu HY; Zhang C; Zhu X; Yuan C; Pu Y
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1275-1284. PubMed ID: 28265739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Volumetric Metabolic Parameters on Preoperative FDG PET/CT for Predicting Tumor Lymphovascular Invasion in Non-Small Cell Lung Cancer.
    Li C; Tian Y; Shen Y; Wen B; He Y
    AJR Am J Roentgenol; 2021 Dec; 217(6):1433-1443. PubMed ID: 33978465
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic significance of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography-derived metabolic parameters in surgically resected clinical-N0 nonsmall cell lung cancer.
    Aktas GE; Karamustafaoğlu YA; Balta C; Süt N; Sarikaya İ; Sarikaya A
    Nucl Med Commun; 2018 Nov; 39(11):995-1004. PubMed ID: 30188416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does FDG PET/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage IA non-small cell lung cancer patients?
    Park HL; Yoo IR; Boo SH; Park SY; Park JK; Sung SW; Moon SW
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1021-1026. PubMed ID: 30756189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary tumor standardized uptake value (SUVmax) measured on
    Hui Z; Wei F; Ren H; Xu W; Ren X
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic tumor burden quantified on [
    Lapa P; Oliveiros B; Marques M; Isidoro J; Alves FC; Costa JMN; Costa G; de Lima JP
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2169-2178. PubMed ID: 28785842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of the 18F-fluorodeoxyglucose positron emission tomography/computed tomography in early-stage nonsmall cell lung cancer.
    Geredeli C; Artac M; Kocak I; Koral L; Sakin A; Altinok T; Kaya B; Karaagac M
    J Cancer Res Ther; 2020; 16(4):816-821. PubMed ID: 32930124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Effects of PET-CT Before Definite Concurrent Chemoradiotherapy in Patients With Unresectable Stage IIIA-IIIB Squamous Cell Carcinoma of the Lungs.
    Lin WC; Chen WM; Chen M; Shia BC; Wu SY
    Clin Nucl Med; 2022 Aug; 47(8):677-683. PubMed ID: 35695702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.
    Pellegrino S; Fonti R; Mazziotti E; Piccin L; Mozzillo E; Damiano V; Matano E; De Placido S; Del Vecchio S
    Ann Nucl Med; 2019 Dec; 33(12):937-944. PubMed ID: 31612416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer.
    Miyazawa T; Otsubo K; Sakai H; Kimura H; Chosokabe M; Morikawa K; Furuya N; Marushima H; Kojima K; Mineshita M; Koike J; Saji H
    Cancer Control; 2021; 28():10732748211038314. PubMed ID: 34384268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.
    Guberina M; Eberhardt W; Stuschke M; Gauler T; Aigner C; Schuler M; Stamatis G; Theegarten D; Jentzen W; Herrmann K; Pöttgen C
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1439-1447. PubMed ID: 30710323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of the Role of PET/CT SUVmax in Prognosis and Its Correlation with 
Clinicopathological Characteristics in Resectable Lung Squamous Cell Carcinoma].
    Ren H; Xu W; You J; Song X; Huang H; Zhao N; Ren X; Zhang X
    Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):192-9. PubMed ID: 27118646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.